EVERSANA, a pioneer of next-generation commercial services to the global life sciences industry, announced a strategic partnership with Integra Connect LLC designed to support life sciences companies as they develop and commercialize new oncology treatments.
Evoke Pharma Inc., a specialty pharmaceutical company primarily focused on treatments for gastrointestinal (GI) diseases, and EVERSANA Life Science Service LLC, an independent provider of global commercial services to the life science industry, announced an extension of their agreement. The companies will continue collaborating on the commercialization and distribution of Gimoti (metoclopramide) nasal spray in the United States through the end of 2026.
Sierra Oncology shared positive topline results from the company’s study on the effectiveness of momelotinib to treat patients with myelofibrosis.
South Korean biotechnology firm ABL Biotechnologies signed a global licensing and exclusive collaboration agreement with Sanofi to develop and commercialize a new therapy candidate for Parkinson’s disease.
After Moderna roared through 2021 on the strength of the company’s COVID-19 vaccine, the mRNA giant forged a partnership with Carisma Therapeutics to develop and commercialize in vivo engineered chimeric antigen receptor monocyte (CAR-M) therapeutics for different forms of cancer.
BioSpace reviewed a busy January 5th for collaboration announcements in the life sciences world.
Ovid Therapeutics has partnered with AstraZeneca for exclusive access to a library of early-stage small molecules that target the KCC2 transporter, including OV350 — the lead candidate.
Angany entered a partnering agreement to evaluate the safety and efficacy of the French-Canadian pharmaceutical company’s lead peanut allergy biological candidate BP/AH-01 with the Food Allergy Center at Massachusetts General Hospital and MassGeneral Hospital for Children.
Biohaven Pharmaceutical Holding and Pfizer have partnered to market the Connecticut-based company’s migraine drug Nurtec ODT (rimegepant) outside of the United States once approved by global regulatory organizations.
Prominent life sciences venture capital firm Flagship Pioneering announced a strategic partnership with the Cystic Fibrosis Foundation on November 3.
